Three New Square Intellectual Property

Thomas’ patents work spans the fields of life sciences, tech and telecoms. His recent cases include AstraZeneca v Glenmark (the most recent appellate decision concerning preliminary injunctions in the pharmaceutical field, and the most recent concerning plausibility), Akebia v Fibrogen (a leading case on the approach to sufficiency of functional claims), and Sandoz, Teva v BMS (the first appellate decision on plausibility following G2/21). He is experienced in economic disputes relating to patents, including FRAND proceedings and damages inquiries such as Dr Reddy’s, NHS England & ors v Warner-Lambert (described by The Lawyer as “potentially the most complicated follow-on damages inquiry ever heard before the Patents Court”). Thomas is a contributing author to Terrell on the Law of Patents, editing the chapters on construction and plausibility. Additionally, he was called to the Irish bar in 2025.

Thomas maintains an active trade marks practice and has worked on cases across diverse sectors including beverages, luxury personal goods, and medical devices. The great majority of his trade mark work reached settlement before trial. In addition to his experience before the High Court, he represents clients unled before the UK IPO.

Thomas is described by clients as a “truly excellent junior” who is “extremely hardworking and intellectually bright” and “provides great client service”.

2019-2020: 12-month pupillage at Three New Square to Miles Copeland, Jeremy Heald, Joe Delaney, Stuart Baran and Geoffrey Pritchard

2018-2019: Legal Assistant at Carpmaels & Ransford LLP. Involved in a pharmaceutical patents matter relating to anti-CGRP antibodies for the treatment of migraine.

2018: Called to the Bar, Lincoln’s Inn

2017-2018:      BPTC at BPP Birmingham: Outstanding; 1st in cohort 2016-2017:      GDL at BPP Birmingham: Distinction 2012-2016:      MChem Chemistry at Lincoln College, Oxford: 1st class